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Sigma-1 receptors (s-1rs) exert neuroprotective effects on retinal ganglion cells (RGCs) both in vivo and
in vitro. This receptor has unique properties through its actions on several voltage-gated and ligand-gated
channels. The purpose of this study was to investigate the role that s-1rs play in regulating cell calcium
dynamics through activated L-type Voltage Gated Calcium Channels (L-type VGCCs) in puriﬁed RGCs.
RGCs were isolated from P3-P7 SpragueeDawley rats and puriﬁed by sequential immunopanning using
a Thy1.1 antibody. Calcium imaging was used to measure changes in intracellular calcium after depo-
larizing the cells with potassium chloride (KCl) in the presence or absence of two s-1r agonists
[(þ)-SKF10047 and (þ)-Pentazocine], one s-1r antagonist (BD1047), and one L-type VGCC antagonist
(Verapamil). Finally, co-localization studies were completed to assess the proximity of s-1r with L-type
VGCCs in puriﬁed RGCs. VGCCs were activated using KCl (20 mM). Pre-treatment with a known L-type
VGCC blocker demonstrated a 57% decrease of calcium ion inﬂux through activated VGCCs. Calcium
imaging results also demonstrated that s-1r agonists, (þ)-N-allylnormetazocine hydrochloride
[(þ)-SKF10047] and (þ)-Pentazocine, inhibited calcium ion inﬂux through activated VGCCs. Antagonist
treatment using BD1047 demonstrated a potentiation of calcium ion inﬂux through activated VGCCs and
abolished all inhibitory effects of the s-1r agonists on VGCCs, implying that these ligands were acting
through the s-1r. An L-type VGCC blocker (Verapamil) also inhibited KCl activated VGCCs and when
combined with the s-1r agonists there was not a further decline in calcium entry suggesting similar
mechanisms. Lastly, co-localization studies demonstrated that s-1rs and L-type VGCCs are co-localized in
puriﬁed RGCs. Taken together, these results indicated that s-1r agonists can inhibit KCl induced calcium
ion inﬂux through activated L-type VGCCs in puriﬁed RGCs. This is the ﬁrst report of attenuation of L-type
VGCC signaling through the activation of s-1rs in puriﬁed RGCs. The ability of s-1rs to co-localize with L-
type VGCCs in puriﬁed RGCs implied that these two proteins are in close proximity to each other and that
such interactions regulate L-type VGCCs.
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The sigma-1 receptor (s-1r) is a 26 kDa protein that was once
categorized as an opioid receptor (Martin et al., 1976; Hanner et al.,
1996). However, further studies have demonstrated that this
receptor is a unique non-opioid receptor with separate pharma-
cological properties including the ability to bind to benzomorphans
(e.g. (þ)-pentazocine and (þ)-SKF10047), steroids (e.g. proges-
terone and testosterone) and psychotropic drugs (e.g. haloperidol)
(Hayashi and Su, 2005). There appear to be several subtypes of
sigma receptors (s-1r and s-2r, and s-3r) (Quirion et al., 1992;
Myers et al., 1994), but s-1r is the only receptor that has been
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1996; Kekuda et al., 1996; Seth et al., 1997, 1998). The endogenous
ligand and function of s-1r is not yet known. This receptor has been
shown to be predominantly localized on the endoplasmic retic-
ulum (ER), with two transmembrane spanning regions, that possess
the ability to translocate to the plasma membrane upon agonist
stimulation or under prolonged stress (Hayashi and Su, 2003; Aydar
et al., 2002). The translocation of s-1r to the plasma membrane is
thought to be the mechanism underlying the ability of an ER
protein like s-1r to modulate and regulate many different ion
channels on the plasma membrane including voltage-gated and
ligand-gated Ca2þ, Kþ, Naþ, Cl, and SK ion channels (Hayashi and
Su, 2003; Aydar et al., 2002; Maurice and Su, 2009; Su et al., 2009).
A number of studies have suggested that s-1r ligands regulate
the activity of voltage gated calcium channels (VGCCs). For
instance, Zhang and Cuevas (2002) demonstrated in para-
sympathetic and sympathetic primary neuronal cultures that s-1r
ligand compounds can facilitate calcium current inactivation of L-,
N-, P/Q-, and R-type VGCCs. In primary hippocampal neurons,
Church and Fletcher (1995) also demonstrated that s-1r ligands
block multiple subtypes of VGCC currents. Hayashi et al. (2000) and
Tchedre et al. (2008) demonstrated in neuronal cell lines that s-1r
agonist stimulation also diminished calcium ion inﬂux through
activated VGCCs.
To date, there have been no reported studies demonstrating s-
1r modulatory effects on any ligand gated ion channels or VGCCs in
puriﬁed retinal ganglion cells (RGCs). Only one study has demon-
strated an inhibitory effect of s-1r agonist stimulation on NMDA
induced calcium ion inﬂux in retinal cross-sections (Zhang et al.,
2011). Therefore, it was important to investigate the role that s-
1r and s-1r ligands play in regulating calcium ion inﬂux in puriﬁed
RGCs.
In this study, we used puriﬁed RGC cultures to study the effects
of two s-1r agonists (SKF10047 and Pentazocine) and one s-1r
antagonist (BD1047) on activated VGCCs in puriﬁed RGCs. The goal
of this study was to evaluate pharmacologically if s-1r ligands act
through the s-1r to attenuate or potentiate calcium ion inﬂux
through activated VGCCs. Lastly, this study aims to identify the
subtype of VGCC that s-1r ligand mediated effects occur in puriﬁed
RGCs.
2. Materials and methods
2.1. Primary RGC isolation
All procedures were performed in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research and were approved by the Institutional Animal Care and
Use Committee (IACUC) at the University of North Texas Health
Science Center. Dr. Ben Barres trained our laboratory to perform his
two-step panning puriﬁed retinal ganglion cell isolation
(Christopherson et al., 2005; Meyer et al., 1995; Ullian et al., 2001;
Barres et al., 1988). Purity utilizing this method has been described
at 96%e99.5% (Christopherson et al., 2005;Meyer et al.,1995; Ullian
et al., 2001; Barres et al., 1988). We found our isolation procedure
resulted in a greater than 98% purity as seen using appropriate cell
markers.
Sprague Dawley rats (post-natal day 3e7) (Charler River, Wil-
mington, MA) were euthanized, and the retinas were placed in
4.5 units/mL of papain solution (Worthington, Lakewood, NJ) to
dissociate the cells. Cells were then incubated for 10 min with
a rabbit anti-macrophage antibody (Cedarlane, Burlington, Ona-
tario, Canada). Cell suspensions were then incubated in a 150-mm
petri dish coated with a goat anti-rabbit IgG (H þ L chain) antibody
(Jackson ImmunoResearch, West Grove, PA) for 30 min. Cells thatdid not adhere to the 150-mm dish were then transferred to a 100-
mmdish coatedwith anti-Thy1.1 antibody (from hybridoma T11D7;
American Type Culture Collection, Rockville, MD) for 45 min. Cells
were then trypsinized off (1250 units/mL) (SigmaeAldrich, St.
Louis, MO) the petri dish and plated on coverslips coated with
mouse-laminin (Trevigen Inc., Gaithersburg, MD). Cells were then
cultured in a serum free deﬁned media, DMEM (Invitrogen, Grand
Island, NY) containing BDNF (50 ng/mL) (Peprotech, Rocky Hill, NJ),
CNTF (10 ng/mL) (Peprotech, Rocky Hill, NJ), and forskolin (5 ng/
mL) (SigmaeAldrich, St. Louis, MO). Cells were incubated at 37 C in
a humidiﬁed atmosphere of 10% CO2 and 90% air.
2.2. Intracellular calcium ([Ca2þ]i) measurement
Puriﬁed RGCs were allowed to incubate in culture for 10 Days
in vitro (D.I.V) before subjecting them to calcium imaging experi-
ments. Intracellular calcium in puriﬁed RGCs wasmeasured at 37 C
by the ratiometric technique using fura-2-AM (excitation at 340 nm
and 380 nm, emission at 510 nm) (Invitrogen, Carlsbad, CA) as
described by Prasanna et al. (2000) utilizing Nikon Eclipse TE2000-
5 microscope and NIS-Elements AR3.2 software (Nikon Instru-
ments, Melville, NY). The Grynkiewicz equation was used to
convert the 340/380 ratio to internal levels of calcium in nanomolar
(nM) concentrations (Grynkiewicz et al., 1985) using the kd value of
224 nM. During the calcium imaging studies, some cells were
pretreated with (þ)-SKF10047 (Tocris, Ellisville, MO), (þ)-Pentaz-
ocine (SigmaeAldrich, St. Louis, MO), BD1047 (Tocris, Ellisville,
MO), or Verapamil (Tocris, Ellisville, MO) for 30 min before they
were stimulated with potassium chloride (KCl). Peak calcium levels
were calculated after KCl administration. Basal levels of cyto-
plasmic calciumwere calculated 30 s prior to the administration of
KCl. Peak cytoplasmic calcium levels were calculated after the
administration of KCl.
2.3. Immunocytochemistry
Puriﬁed retinal ganglion cells were grown on coverslips and
ﬁxed with 100% methanol at 20 C for 10 min or incubated at
room temperature with paraformaldehyde for 15 min. These cells
were then blocked with 5% normal donkey serum for 2 h at room
temperature. Blocking solution was removed and cells were then
incubated with primary antibodies: afﬁnity-puriﬁed s-1r mono-
clonal antibody (1/50 dilution; Santa Cruz Biotechnology, Santa
Cruz, CA), voltage-dependent L-type-1C subunit antibody (1/100;
Millipore, Temecula, CA), or Thy1.1 monoclonal antibody (1/100
dilution; Santa Cruz Biotechnology, Santa Cruz, CA) at 4 C over-
night. Coverslips were then washed three times with PBS, and
a 1:1000 dilution of secondary antibodies donkey anti-rabbit IgG
(Alexa Fluor 648) conjugate and donkey anti-mouse IgG (Alexa
Fluor 488) conjugate (Invitrogen, Carlsbad, CA) were added and
incubated for 1 h in the dark. After incubation, the coverslips were
washed again three times with PBS. Mounting was performed on
glass slides using antifade reagent with DAPI (Prolong Gold; Invi-
trogen, Carlsbad, CA) and allowed to dry for 20 min in the dark.
Cells were viewed on a confocal laser scanning microscope (LSM
510; Zeiss, Thornwood, NY).
2.4. Co-localization with immunoﬂuorescence staining
Confocalmicroscopywas performed using a Zeiss LSM510META
laser-scanning microscope (Carl Zeiss, Inc., Thornwood, NY) equip-
ped with a 40 objective, using the following laser wavelengths:
excitation 488 nm, emission 505e530 nm or excitation 648 nm,
emission 630e700 nm. Quantiﬁcations of the co-localization coef-
ﬁcients, derived from measured pixel overlaps between sigma-1
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formed using a free, open source software package, BioImageXD
(Kankaanpää et al., 2006). To quantify the level of co-localization, 9
cells were randomly selected from 3 separate experiments and
optically sectioned using confocal microscope. At least 15 z-slices at
0.25 mm thickness were obtained per cell. Co-localization was
evaluated from the center slice of the cell by examination of the
merged images and analysis was performed with BioImageXD. The
co-localization thresholds were calculated automatically by the
BioImageXD software, as recommended by Costes et al. (2004). As
described byManders et al., 1993, co-localization coefﬁcient 1 (M1/
tM1) and co-localization coefﬁcient 2 (M2/tM2) were used to
identify the proportion of overlap between one protein on another.
Utilizing Manders coefﬁcients calculations enable co-localization
coefﬁcients to be calculated independent of the relative intensities
of the two different channels (Manders et al., 1993). A pseudo color
of yellow was utilized to depict co-localization of sigma-1 receptor
with the L-VGCC.
2.5. Western blot analysis
Primary neurons were homogenized in 100 mL of ice cold buffer
containing 50 mM Tris, pH 7.4, 10 mM Mg2þ, 1 mM EDTA, 1 mM
EGTA, 10 mM benzamide, 100 ng/mL leupeptin, 100 ng/mL apro-
teinin, 0.08 mM sodium molybdate, 0.01% triton-100, 10 mM oka-
doic acid, and 2 mM sodium pyrophosphate. Lysed aliquots were
sonicated and taken for protein concentration estimation using
protein assay reagent (Bio-Rad Laboratories, Hercules, CA). Samples
were then electrophoresed on a pre-cast ready-made SDS/PAGE
gradient gel (Bio-Rad Laboratories, Hercules, CA). The protein was
then transferred onto a PVDF membrane (Millipore, Billerica, MA)
overnight at 4 C. Membranes were then blocked for 1 h with 4%
non-fat dried milk (Bio-Rad Laboratories, Hercules, CA), and then
probed overnight at 4 C. A mouse monoclonal antibody against
sigma-1 receptor (Santa Cruz Biotechnology, Santa Cruz, CA) was
used at a 1:1000 dilution. A polyclonal antibody against voltage-
dependent L-type-1C subunit antibody (Millipore, Temecula, CA)
was used at a 1:1000 dilution. Membranes were then incubated at
room temperature for 1 h with a horseradish peroxidase conju-
gated secondary antibody (Bio-Rad Laboratories, Hercules, CA) at
a dilution of 1:1000. The proteins were then visualized with
supersignal chemiluminesence (Pierce Biotechnology, Rockford, IL)
using UVP software (Upland, CA).
2.6. Total Internal Reﬂection Fluorescence Microscopy (TIFRM)
TIRFM was used to obtain images of the cell membrane from
a distance of 100 nm from the coverslip to be thin enough to allow
only the plasma membrane to get illuminated. The Olympus IX71
ﬂuorescence microscope (Olympus America Inc., Melville, NY) was
used to measure single cell evanescent ﬁeld ﬂuorescence (EFF)
intensity using an Olympus 60/1.45 Oil objective. Cells were
excited with 488 nm with an argon air-cooled laser (Melles Griot,
Albuquerque, New Mexico). Fluorescence images were collected
with a back-illuminated electron-multiplying charge-coupled
device (EMCCD) camera (Hamamatsu Photonics, Japan). Simple
PCI software was used to control the protocol of acquisition and to
perform data analysis.
2.7. Data analysis
Statistical signiﬁcance of differences between values was eval-
uated by performing one-tailed unpaired t-test for two group
comparisons and ANOVA followed by Student-NewmaneKeuls
post hoc test for multiple group comparisons. Experimental datawith values of p < 0.05 were considered to be statistically
signiﬁcant.
3. Results
3.1. Puriﬁed rat retinal ganglion cell culture
Retinas were isolated from P3 to P7 Sprague Dawley rat pups.
Utilizing a double immunopanning technique described by Barres
et al. (1988), microglia were eliminated from the mixed culture
by panning with an anti-macrophage antibody. RGCs were then
collected from the retinal cell population by panning with a T11D7
(anti-thy1.1) antibody. Cells were allowed to mature for 10 days
before subjecting them to immunocytochemistry analysis. Fig. 1A
and B, demonstrate that the majority of DAPI stained RGCs are
thy1.1 positive. Fig. 1C and D demonstrate negative controls and in
1D where immunostaining was performed with the exclusion of
the primary antibody.
3.2. Expression of sigma-1 receptor and L-type VGCCs in puriﬁed
RGCs in culture
To determine whether s-1 receptor and L-type VGCC were
expressed in our puriﬁed primary RGCs, we examined extracts from
puriﬁed P10 RGCs byWestern blot analysis. s-1 receptor and L-type
VGCC were detected in RGC extracts after 10 days in culture (Fig. 2).
3.3. Plasma membrane staining (TIRFM) of sigma-1 receptor and
co-localization of sigma-1 receptor and L-type Voltage Gated
Calcium Channel in puriﬁed retinal ganglion cells
To determine the localization of s-1 receptors and L-type VGCCs,
we performed immunostaining on RGCs after 10 days in culture
using a s-1 receptor and L-type VGCC speciﬁc antibodies. Total
Internal Reﬂection Fluorescence Microscopy (TIRFM) revealed that
immunoreactivity for s-1 receptors was distributed throughout the
plasma membrane of the soma and proximal neurites of our puri-
ﬁed RGCs (Fig. 3B). Bright ﬁeld microscopy images were obtained of
the puriﬁed RGCs (Fig. 3A). Confocal immunocytochemistry was
performed looking at the L-type VGCC and the s-1r (Fig. 3CeF). As
described in Section 2.4, Z-stack sections of 0.25 mm thickness were
taken on the Zeiss 510 confocal and the extenet of pixel overlap in
the merged images was calculated using the BioImageXD software.
Co-localization calculations conﬁrm inpuriﬁed RGCs that about 50%
of the L-type VGCCs are co-localized with s-1rs and that 67% of the
s-1rs are co-localized with L-type VGCCs (Fig. 3F, depicted as
yellow, and 3G). This data suggests that the L-type VGCC and the s-
1r are co-compartmentalized in similar cellular locations in puriﬁed
RGCs.
3.4. KCl-induced calcium inﬂux in puriﬁed RGCs is mediated
through L-type VGCCs in an extracellular calcium dependent
manner
We initiated a set of Ca2þ imaging experiments to assess the
fraction of the KCl-activated Ca2þ concentration change on puriﬁed
RGCs (Fig. 4A and B). In addition, puriﬁed RGCs were incubated in
Verapamil (10 mM) (a known L-type VGCC blocker) for 30 min prior
to KCl stimulation to assess the percentage of L-type VGCCs that
were activated by KCl stimulation (Fig. 4A and B). Before the
stimulation of KCl, the average baseline [Ca2þ]i levels were equal to
149  8 nM (n ¼ 110) and 154  16 nM (n ¼ 31) for control KCl
stimulated cells and for Verapamil (10 mM) treated cells. Treatment
with KCl to elicit puriﬁed RGC depolarization robustly increased
cytoplasmic calcium in puriﬁed RGCs to 1942  118 nM (n ¼ 110)
Fig. 1. Characterization of isolated RGCs utilizing a double immunopanning procedure described by Barres et al. (1988). Purity of RGCs was assessed through immunocytochemical
analysis of RGC speciﬁc markers of Thy-1.1. Thy1.1 was detected in almost all DAPI stained cells in our puriﬁed cultures. Top panel represents staining with speciﬁc primary antibody
(A) nuclei stained with DAPI (blue). (B) Immunolabeling of primary RGCs with an antibody against Thy-1.1 (Green); nuclei stained with DAPI (blue). Bottom panel represents the
negative control in which immunostaining was performed with the exclusion of the primary antibody. (C) Blank. (D) Donkey anti-Rabbit alexa 488 alone. Scale bar, 100 mm.
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calcium stimulation to 838  81 nM (n ¼ 31). These results suggest
that KCl stimulation in puriﬁed RGCs mediates 57% of the calcium
ion inﬂux through L-type VGCCs and 43% of the calcium ion inﬂux
through non-L-type VGCCs. To determine that extracellular calcium
was required for KCl-induced calcium signaling, extracellular
calcium was removed from the buffer, and there was no KCl stim-
ulated calcium inﬂux until 2.5 mM of CaCl2 was administered to the
extracellular calcium buffer solution (Fig. 4C).Fig. 2. Puriﬁed RGCs express s-1r and L-type VGCC in vitro. Immunoblots performed
on cellular lysates from P3-P7 RGCs after 10 days in culture show the expression of s-
1r and L-type VGCCs.3.5. SKF-10047 (Sigma-1 receptor agonist) decreases peak calcium
ion inﬂux through VGCCs in a dose dependent manner while
antagonizing sigma-1 receptor potentiates peak calcium ion inﬂux
through VGCCs
It has been reported previously in a non-retinal ganglion cell
line that (þ)-SKF10047 (s-1 receptor agonist) decreased calcium
ion inﬂux following KCl stimulation (Tchedre et al., 2008). To
determine if (þ)-SKF10047 had a concentration dependent effect
on the attenuation of KCl induced calcium ion inﬂux in puriﬁed
RGCs, calcium imaging was performed with fura-2-AM Ca2þ
imaging dye following treatment with different doses of
(þ)-SKF10047. Puriﬁed RGCs were pre-incubated with 100 nM,
1 mM, and 10 mM of (þ)-SKF10047 for 30 min prior to KCl stimu-
lation (Fig. 5AeC). Average baseline [Ca2þ]i levels were equal to
149 nM  8 (n ¼ 110), 148 nM  12 (n ¼ 53), 110 nM  12 (n ¼ 37),
and 101 nM  15 (n ¼ 42) for untreated control cells, and cells
treatedwith 100 nM,1 mM, and 10 mMof (þ)-SKF10047 respectively
(Fig. 5B). Peak KCl induced [Ca2þ]i levels were equal to
1942 nM  118 (n ¼ 110), 1835 nM  150 (n ¼ 53), 1271 nM  138
(n ¼ 37), and 1382 nM  150 (n ¼ 42) for untreated control cells,
and cells treated with 100 nM, 1 mM, and 10 mM of (þ)-SKF10047
respectively (Fig. 5A).
To determine the contribution of endogenous s-1 receptor to
the calcium signaling response, puriﬁed RGCs were ﬁrst pre-
incubated with 100 nM, 1 mM, and 10 mM of BD1047 (s-1 antago-
nist) for 30 min prior to KCl stimulation (Fig. 5D and E). For the s-1
receptor antagonist treated cells (BD1047) average baseline [Ca2þ]i
levels were equal to 149 nM  8 (n ¼ 110), 168 nM  21 (n ¼ 52),
Fig. 3. TIRFM indicating plasma membrane localization of s-1 and immunocytochemical colocalization of s-1 receptor and L-type VGCCs in puriﬁed RGCs. (A) Bright Field
Microscopy image of puriﬁed RGCs used for TIRFM analysis. (B) TIRFM image of puriﬁed RGCs demonstrating s-1 expression on the plasma membrane of primary RGCs. (C) DIC
image of RGC; (D) L-type Voltage Gated Calcium Channel (VGCC) expression (Red) and DAPI (Blue) and (E) s-1 receptor expression (Green) and DAPI (Blue). Z-stack images were
obtained at 0.25 mm intervals in a Zeiss 510 confocal microscopy for D, E and F. Bars, 20 mm. (F) Merged pictures of D and E, demonstrated co-localization of the two proteins (co-
localizing voxels are presented as yellow). Bars, 20 mm. (G) Co-localization calculations demonstrate that 50% of L-type VGCCs are co-localized with s-1 receptors, and that 67% of
s-1 receptors are co-localized with L-type VGCCs.
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control cells, and cells treated with 100 nM, 1 mM, and 10 mM of
BD1047 respectively. For peak KCl induced [Ca2þ]i levels were equal
to 1942 nM 118 (n¼ 110),1707 nM 190 (n¼ 52), 2650 nM 344
(n ¼ 34), and 1898 nM  154 (n ¼ 61) for untreated control cells,
and cells treated with 100 nM, 1 mM, and 10 mM of BD1047
respectively (Fig. 5D and E).
These results suggested that (þ)-SKF10047 (100 nM, 1 mM, and
10 mM) was able to signiﬁcantly inhibit baseline levels of cyto-
plasmic calcium and KCl-induced calcium signaling in a dose
dependent manner (p < 0.05) (Fig. 5AeC). These results also sug-
gested that the s-1r antagonist BD1047 potentiated KCl-induced
calcium signaling at 1 mM (p < 0.01) (Fig. 5D and E). Additionally
at 10 mM treatment, BD1047 signiﬁcantly increased the baselinelevel of cytoplasmic calcium by 2 fold (p < 0.001), but had no effect
on peak level of KCl-induced calcium signaling (Fig. 5E).
3.6. Sigma-1 receptor agonists decreased KCl-Induced calcium ion
inﬂux in puriﬁed RGCs which is reversed by a Sigma-1 receptor
antagonist treatment
Pentazocine was also tested to investigate if another s-1
receptor agonist pretreatment 30 min before KCl stimulation could
decrease calcium ion inﬂux through KCl stimulated VGCCs in
puriﬁed RGCs. Average baseline [Ca2þ]i levels were equal to
149 nM  8 (n ¼ 110), 110 nM  12 (n ¼ 37), and 186 nM  15
(n ¼ 53) for untreated control cells, and cells treated with
(þ)-SKF10047 (1 mM) or Pentazocine (1 mM). Peak KCl induced
Fig. 4. KCl depolarization produced an increase in cytoplasmic calcium response through VGCCs in an extracellular calcium dependent manner. KCl-induced calcium inﬂux was
measured by fura-2-AM imaging. Cells were preincubated for 30 min with either fura-2-AM or fura-2-AM and Verapamil (10 mM) before stimulating the cells with 20 mM KCL.
(A) Verapamil signiﬁcantly inhibited KCl-induced calcium inﬂux in puriﬁed RGCs. Values are mean  SEM (n ¼ 110 for KCl; n ¼ 31 for Verapamil þ KCl) (***p < 0.001).
(B) Representative [Ca2þ]i trends in response to KCl and KCl þ Verapamil (10 mM). (C) Representative tracing depicting the effect of extracellular calcium on KCl-induced calcium
signaling. Puriﬁed RGCs were preincubated with fura-2-AM in a calcium-free buffer for 30 min before stimulation with KCl in the absence and presence of calcium (2.5 mM).
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1271 nM  138 (n ¼ 37), and 1412 nM  77 (n ¼ 53) for untreated
control cells, and cells treated with (þ)-SKF10047 (1 mM) or
Pentazocine (1 mM) (Fig. 6A and B).
To determine if the suppression of KCl-induced calcium ion
inﬂux with the two s-1 receptor agonists was being mediated
through the s-1 receptor, calcium imaging experiments were per-
formed with the co-application of BD1047 (s-1 receptor antago-
nist) either with SKF10047 or Pentazocine (Fig. 6C and D). Puriﬁed
RGCswere treatedwith BD1047 5min prior to the administration of
the two s-1 receptor agonists. Cells were then incubated for 30 min
with both agonist and antagonist before KCl stimulation. Average
baseline [Ca2þ]i levels were equal to 118 nM 8 (n¼ 43), 85 nM 8
(n ¼ 34), and 82 nM  15 (n ¼ 31) for untreated control cells, and
cells treated with a combination of either BD1047 (10 mM) and
(þ)-SKF10047 (1 mM), or cells treated with BD1047 (10 mM) and
Pentazocine (1 mM) respectively. Peak KCl induced [Ca2þ]i levels
were equal to 800 nM  70 (n ¼ 43), 700 nM  101 (n ¼ 34), and
753 nM  90 (n ¼ 31) for untreated control cells, and cells treated
with a combination of either BD1047 (10 mM) and (þ)-SKF10047 at
1 mM, or with BD1047 (10 mM) and Pentazocine (1 mM) respectively
(Fig. 6C and D).
(þ)-SKF10047 (1 mM) and pentazocine (1 mM), signiﬁcantly
suppressed the peak KCl-induced calcium ion inﬂux by 35%
(p < 0.01) and 27% (p < 0.01) respectively (Fig. 6A and B). Addi-
tionally, the co-administration of a s-1 receptor agonist with a s-1
receptor antagonist blocked the s-1 agonist induced suppression of
peak KCl-induced calcium ion inﬂux (Fig. 6C and D). These resultssuggested that the blockade effect observed by both (þ)-SKF10047
and pentazocine were mediated through the s-1 receptor and not
some other non-speciﬁc ligand binding site. The results are in
agreement with Hayashi et al. (2000) that found in NG108 cells that
s-1r agonist effects on activated VGCCs were able to be abolished
through the co-application of an antisense oligodeoxynucleotide
targeted against s-1r, and Tchedre et al. (2008) who also demon-
strated in a non-retinal ganglion cell line that s-1r agonist effects
on activated VGCCs were acting via the s-1r through the ability to
block the agonist mediated effects by the co-treatment of a s-1r
antagonist.
3.7. Sigma-1 receptor mediated effects on KCl induced calcium ion
inﬂux were mediated through the L-type voltage gated calcium
channel
Studies have suggested that there is a direct interaction between
s-1 and L-type VGCCs (Tchedre et al., 2008). We wanted to deter-
mine if the observed s-1 receptor ligand effects on KCl induced
calcium ion inﬂux were being mediated through the L-type VGCCs
or other VGCCs in puriﬁed RGCs. To address this issue, puriﬁed RGCs
were co-treated with a s-1 receptor ligand (SKF-10047, Pentazo-
cine, or BD1047) and Verapamil (L-type VGCC blocker). Cells were
ﬁrst treated with Verapamil (10 mM) 5 min before the administra-
tion of a s-1 receptor ligand. These cells were then incubated
for 30minwith both Verapamil and s-1 receptor ligand prior to KCl
stimulation. Average baseline [Ca2þ]i levels were equal to
118 nM  8 (n ¼ 43), 80 nM  9 (n ¼ 44), 113 nM  12 (n ¼ 41),
Fig. 5. The effect of sigma-1 receptor agonist, (þ)-SKF10047, and antagonist on basal level of cytoplasmic calcium and KCl-induced calcium inﬂux in puriﬁed RGCs. KCl-induced
calcium inﬂux was measured by fura-2-AM imaging. Cells were incubated with fura-2-AM with and without (þ)-SKF10047 for 30 min before stimulating the cells with KCl.
After treatment, all drugs remained in the bath solution for the duration of the calcium imaging experiments. (A) Sigma-1 agonist, (þ)-SKF10047, inhibited KCl-induced calcium
inﬂux in a concentration-dependent manner. Values are represented as mean  SEM (n ¼ 110 for KCl; n ¼ 53 for KCl þ (þ)-SKF10047 (100 nM); n ¼ 37 for KCl þ (þ)-SKF10047
(1 mM); n ¼ 42 for KCl þ (þ)-SKF10047 (10 mM)) (** ¼ p < 0.01 and * ¼ p < 0.05). (B) Summary of the effects that (þ)-SKF10047 has on basal level of cytoplasmic calcium. Values are
mean  SEM (n ¼ 110 for KCl; n ¼ 53 for KCl þ (þ)-SKF10047 (100 nM); n ¼ 37 for KCl þ (þ)-SKF10047 (1 mM); n ¼ 42 for KCl þ (þ)-SKF10047 (10 mM)) (**p < 0.01 and *p < 0.05).
(C) Representative tracing depicting the effect of various concentrations of (þ)-SKF10047 on KCl induced peak [Ca2þ]i. (D) Sigma-1 antagonist, BD1047 (1 mM), demonstrated
a statistical signiﬁcant potentiation of KCl-induced calcium inﬂux. Values are represented as mean  SEM (n ¼ 110 for KCl; n ¼ 52 for KCl þ BD1047 (100 nM); n ¼ 34 for
KCl þ BD1047 (1 mM); n ¼ 61 for KCl þ BD1047 (10 mM)) (**p < 0.01). (E) Representative graph depicting the effect of various concentrations of BD1047 on KCl induced peak [Ca2þ]i.
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cells, or cells treated with Verapamil (10 mM), or with a combina-
tion of either Verapamil (10 mM) and BD1047 (1 mM), or Verapamil
(10 mM) and (þ)-SKF10047 (1 mM), or Verapamil (10 mM) and
(þ)-pentazocine (1 mM) respectively. Peak KCl induced [Ca2þ]i
levels were equal to 800 nM  70 (n ¼ 43), 342 nM  56 (n ¼ 44),
286 nM  35 (n ¼ 41), 332 nM  41 (n ¼ 43), and 234 nM  36
(n ¼ 42) for untreated control cells, or cells treated with Verapamil
(10 mM), or with a combination of either Verapamil (10 mM) and
BD1047 (1 mM), or Verapamil (10 mM) and (þ)-SKF10047 (1 mM), or
Verapamil (10 mM) and (þ)-pentazocine (1 mM) respectively
(Fig. 7A and B). The control untreated cells had a statistically
signiﬁcant increase in KCl induced [Ca2þ]i compared to all other
treated cells, p < 0.001 (Fig. 7A and B). However, there was no
difference in KCl induced [Ca2þ]i amongst all the treated cells. These
results suggest that the s-1 receptor ligand mediated effects in
Figs. 4e6 were all acting through s-1 receptor to modulate the L-
type VGCCs.
These results suggest, for the ﬁrst time in primary RCGs, that s-1
receptor stimulation (Fig. 8) regulates [Ca2þ]i inﬂux through L-type
VGCCs (Fig. 8B). Also, the antagonizing of s-1 receptor appears to
increase [Ca2þ]i inﬂux through L-type VGCCs (Fig. 8C). This implies
that perhaps s-1 receptor has a homeostatic regulatory role in theregulation of L-type VGCCs which is independent of ligand binding
(Fig. 8A).
4. Discussion
Two s-1r agonists (SKF10047 and (þ)-pentazocine) decreased
calcium ion inﬂux through KCl stimulated VGCCs, while co-
treatment with a s-1r antagonist (BD1047) abolished the inhibi-
tory effect of the two s-1r agonists, suggesting that the agonist
effects were mediated through s-1rs. The co-treatment of a known
L-type VGCC blocker (Verapamil) with the two s-1r agonists
resulted in no further decrease in calcium ion inﬂux through the
activated VGCCs when compared to RGCs treated with verapamil
alone. Taken together, our study suggests that s-1r receptor stim-
ulation attenuates calcium inﬂux through L-type VGCCs and this is
being reported for the ﬁrst time in puriﬁed RGCs.
The data supports previous observations in other tissues that s-
1r ligands impede calcium ion inﬂux through activated VGCCs.
However, our results in puriﬁed RGCs differ from previous studies
in other cell types, by speciﬁcally identifying L-type VGCCs and not
other sub-types of VGCCs, as the main target of s-1r activation.
Other studies also demonstrate that s-1r ligands act independent
of s-1r to block VGCCs. Research in hippocampal neurons (Church
Fig. 6. Effect of sigma-1 receptor ligand (þ)-SKF10047 (1 mM) and pentazocine (1 mM) on KCl-induced (20 mM) peak calcium inﬂux in primary RGCs. KCl-induced calcium inﬂux was
measured by fura-2-AM imaging. In calcium imaging studies, cells were preincubated for 30 min with fura-2-AM alone, fura-2-AM þ (þ)-SKF10047, or fura-2-AM þ pentazocine.
(A) Sigma receptor agonists ((þ)-SKF10047 and pentazocine) inhibited KCl-induced peak calcium inﬂux in primary RGCs. Values are mean  SEM (n ¼ 110 for KCl; n ¼ 37 for
KCl þ (þ)-SKF10047; n ¼ 53 for KCl þ pentazocine) (**p < 0.01). (B) Representative tracing depicting the effect of (þ)-SKF10047 or pentazocine on KCl induced peak [Ca2þ]i. (C) Co-
treatment of a sigma-1 receptor antagonist abolished the inhibitor effects of (þ)-SKF10047 and pentazocine on KCl-induced peak calcium inﬂux in primary RGCs. Values are
mean  SEM (n ¼ 43 for KCl; n ¼ 34 for KCl þ (þ)-SKF10047 (1 mM) þ BD1047 (1 mM); and n ¼ 31 for KCl þ pentazocine (1 mM) þ BD1047 (1 mM)). (D) Representative tracing
depicting the effect of BD1047 treatment on (þ)-SKF10047 or pentazocine on KCl induced peak [Ca2þ]i.
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(Zhang and Cuevas, 2002) demonstrated that s-1r ligands, both
agonist (pentazocine) and antagonist (haloperidol), at high micro-
molar concentrations decreased calcium ion inﬂux through all
VGCCs in a s-1r independent manner. Similarly, a study performed
using mouse forebrain synaptosomes demonstrated that s-1r
ligand treatment at high micromolar concentrations (agonist
(pentazocine) and antagonist (BD10047)) decreased calcium ion
inﬂux through non-L type VGCCs in a s-1r independent manner
(González et al., 2012).
An explanation for the difference in these results could be the
differing response of various neuronal cell types and doses of s-1r
ligands used to treat these neuronal cultures in each of these
experimental paradigms. Blockade of VGCCs by pentazocine (s-1r
agonist) was observed only at doses  100 mM in the studies per-
formed in primary hippocampal neurons and parasympathetic and
sympathetic neurons (Zhang and Cuevas, 2002; Church and
Fletcher, 1995). It is unclear if these two studies could demon-
strate blockade of VGCCs with pentazocine at lower micromolar or
nanomolar concentrations because they did not report any data at
those lower pharmacological concentrations (Zhang and Cuevas,
2002; Church and Fletcher, 1995). González et al. (2012) reported
that in the mouse forebrain synaptosomes that they were unable to
block stimulated VGCCs with pentazocine at concentrations at
10 mM. Our results are in agreement with this ﬁnding since themouse forebrain synaptosomes do not have L-type VGCCs (Alvarez
et al., 1995; Meder et al., 1997).
The studies described above used high micromolar concentra-
tions of s-1r ligands and this may result in binding to other
receptors that could produce confounding effects on VGCCs. For
instance, haloperidol is a very well-studied s-1r antagonist;
however, it has been demonstrated to have strong antiadrenergic,
antihistaminic, and anti-serotonin activity. Pentazocine, widely
used as a s-1r agonist, has partial agonistic like effects on m and 8
opioid receptors. Therefore, when high micromolar concentrations
of s-1r ligands are used, it is difﬁcult to clearly identify the
mechanism associated with actions on the VGCCs.
Our ﬁndings concur with those from other studies demon-
strating the ability of s-1r ligands to modulate calcium ion inﬂux
through activated VGCCs in a s-1 receptor dependent manner
(Hayashi et al., 2000; Tchedre et al., 2008; Tchedre and Yorio, 2008).
Since we demonstrated that the s-1r agonist-like effects on VGCCs
were reversed by a co-application of BD1047 (s-1r antagonist), it
appears that s-1r has a functional relationship on the attenuation
of VGCCs, and speciﬁcally the L-type VGCCs, in puriﬁed RGCs.
Another interesting point in our study was that BD1047 (s-1r
antagonist) produced an increased response to KCl induced calcium
signaling in RGCs (Fig. 5). This is in agreement with a previous study
that demonstrated that BD1047 had an opposite effect compared to
a s-1r agonist on intracellular calcium mobilization (Novakova
Fig. 7. Effect of sigma-1 receptor ligands (1 mM) co-treated with the L-type VGCC blocker Verapamil (10 mM) on KCl-induced (20 mM) peak calcium inﬂux in puriﬁed RGCs. KCl-
induced calcium inﬂux was measured by fura-2-AM imaging. In calcium imaging studies, cells were preincubated for 30 minwith fura-2-AM alone, fura-2-AM þ Verapamil (10 mM),
fura-2-AM þ Verapamil þ BD1047, fura-2-AM þ Verapamil þ (þ)-SKF10047, or fura-2-AM þ Verapamil þ pentazocine. (A) Verapamil inhibited KCl-induced peak calcium inﬂux in
primary RGCs by 57%. There was no appreciable difference in KCl-induced peak calcium inﬂux for cells treated with Verapamil and cells treated with Verapamil and sigma-1
receptor ligands. Values are mean  SEM (n ¼ 43 for KCl treated cells; n ¼ 44 for KCl þ Verapamil (10 mM); n ¼ 41 for KCl þ Verapamil (10 mM) þ BD1047 (1 mM); n ¼ 43 for
KCl þ Verapamil þ (þ)-SKF10047; and n ¼ 42 for KCl þ Verapamil þ Pentazocine) (***p < 0.001). (B) Representative tracing depicting the effect Verapamil (10 mM), Verapamil
(10 mM) þ BD1047 (1 mM), Verapamil (10 mM) þ (þ)-SKF10047, or Verapamil (10 mM) þ pentazocine on KCl induced peak [Ca2þ]i.
B.H. Mueller II et al. / Experimental Eye Research 107 (2013) 21e31 29et al., 1998). Several reports have also demonstrated that s-1r can
alter channel functions in the absence of a ligand implying that this
receptor has baseline effects (Aydar et al., 2002; Tchedre and Yorio,
2008). Our results suggest that BD1047 diminished the homeostatic
regulation of s-1r on L-type VGCCs, and subsequently caused an
increase of calcium signaling likely through the L-type VGCC.Fig. 8. Sigma-1r appears to have a homeostatic role in regulating calcium ion inﬂux through
through L-type VGCCs. (B) Sigma-1 receptor agonist stimulation decreases [Ca2þ]i through L
inﬂux through L-type VGCCs.This potentiation effect of BD1047 was observed at 1 mM
concentrations but was non-existent at 10 mM concentrations.
These anomalous pharmacological effects can be explained by
another study that demonstrated that a 10 mM treatment of BD-
1047 decreased KCl induced calcium ion inﬂux in non-L-type
VGCCs in mouse forebrain synaptosomes isolated from s-1rRGCs. (A) Under normal conditions, s-1r may have a role in attenuating [Ca2þ]i inﬂux
-type VGCCs. (C) When s-1rs are antagonized, there is an increased level of [Ca2þ]i by
B.H. Mueller II et al. / Experimental Eye Research 107 (2013) 21e3130knockout mice (González et al., 2012). Therefore, it could be
possible in puriﬁed RGCs that BD1047 at higher micromolar
concentrations can be simultaneously potentiating calcium ion
inﬂux through L-type VGCCs while activating other mechanisms
that could be diminishing calcium ion inﬂux through other non-L-
type VGCCs. In addition, there have been described sub-
populations of retinal ganglion cells (REF) and this could result in
heterogeneity of the response.
The detailed molecular signaling pathways responsible for s-1r
mediated regulation of different ion gated and voltage gated
channels remains largely unknown. Studies have proposed that
s-1rs modulate intracellular signaling transduction through direct
proteineprotein interactions (Tchedre et al., 2008; Aydar et al.,
2002; Lupardus et al., 2000). So far, s-1r has been co-
immunoprecipitated with L-type VGCCs (Tchedre et al., 2008) and
potassium channels (Aydar et al., 2002; Lupardus et al., 2000). Our
co-localization data in puriﬁed RGCs is in agreement with the above
studies, and suggest that s-1r is co-localized with L-type VGCCs in
puriﬁed RGCs. In addition, Fig. 3 demonstrates through TIRF anal-
ysis that s-1rs are present on neuronal plasma membrane of RGCs.
This provides further evidence that in puriﬁed RGCs, s-1r and L-
type VGCCs are at the very least in close proximity to one another
and have the potential to interact. However, some reports have also
linked s-1rs to the activation and modulation of G-protein coupled
receptors (Zhang et al., 2011; Morin-Surun et al., 1999; Soriani et al.,
1999; Ueda et al., 2001; Meyer et al., 2002). It is possible that this
may be another mechanism that s-1rs utilize to modulate calcium
signaling through L-type VGCCs.
There have been numerous studies demonstrating neuro-
protection of RGCs by blocking calcium ion inﬂux through VGCCs.
Intraperitoneal injections of nifedipine (L-type VGCC blocker)
protected rats from ischemia-induced retinal degeneration damage
(Crosson et al., 1990). Lomerizine, another L-type VGCC blocker, has
been shown in vitro and in vivo studies to provide neuroprotection
to retinal neurons when they were subjected to ischemic condi-
tions (Toriu et al., 2000). Lastly, betaxolol, demonstrated neuro-
protective like effects on RGCs. Betaxolol is commonly known as an
intraocular pressure lowering agent, but was hypothesized to have
its neuroprotective effects through its ability to block calcium ion
inﬂux through L-type VGCCs (Hirooka et al., 2000). Similar to the
compounds above, it is possible that s-1r activation can mediate its
RGC neuroprotective effects through its ability to partially block
calcium ion inﬂux through activated L-type VGCCs.
In conclusion (Fig. 8), we demonstrate for the ﬁrst time in
puriﬁed RGCs that the activation of s-1rs following agonist stim-
ulation results in a suppression of calcium signaling through
L-type VGCCs. We also demonstrate that antagonizing s-1rs
with an antagonist potentiates cytoplasmic calcium ion inﬂux
through L-type VGCCs. It is unclear if the s-1r mediated effects
on L-type VGCCs in primary RGCs are due to a direct proteine
protein interaction, or some other secondary mechanism. Future
studies are needed to investigate how this dynamic receptor
interacts with L-type VGCCs in primary RGCs. The elucidation of
this mechanism may help identify the endogenous function of
this receptor, and may help explain how this receptor is
neuroprotective.
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